Vetivax

Vetivax is a veterinary biotechnology company that develops personalized cancer immunotherapies for companion animals, including dogs, cats, and horses. The company's core technology is an autologous cancer vaccine, branded as VetiVax, which is custom-manufactured using a sample of the patient's own tumor tissue to trigger a specific immune response against cancer cells. This treatment is designed to be used following surgical debulking of a tumor, aiming to prevent recurrence and metastasis with minimal side effects compared to traditional chemotherapy. Vetivax provides veterinarians with a specialized kit for tumor collection and delivers the finished vaccine for administration in a clinical setting. The company's approach focuses on leveraging the patient's unique tumor profile to provide a targeted, low-toxicity treatment option.